A large seroepidemiologic and genotyping study of hepatitis C virus (HCV) was conducted in Lima, Peru, during the periods of 1986 to 1993 (cohort A) and 1994 (cohort B). Anti-HCV seroprevalence rates were 15.6% (216 of 1,389) and 11.7% (168 of 1,438), respectively. Low rates were seen among volunteer blood donors (1.1% and 0.8%). Anti-HCV rates were much higher among patients undergoing hemodialysis (43.7% and 59.3%), hemophiliacs (60.0% and 83.3%), in those more than 39 years old (18.2% and 26.0%), in females (25.0% and 27.4%), and in less-educated persons (16.9%). Age-and gender-adjusted risk factors in cohort B included blood transfusion history (adjusted odds ratio [AOR] ϭ 29.8), prior organ transplantation (AOR ϭ 9
INTRODUCTION
Hepatitis C virus (HCV) is the major cause of parenterally transmitted non-A, non-B hepatitis worldwide and is the most common blood-borne infection in the United States. 1 In the United States alone, it is estimated that approximately 36,000 new infections occur each year 2 and an estimated 3.9 million (1.8%) of the population is infected. 3 After one or more decades, up to 20% of chronically infected patients develop cirrhosis, with a concomitant increase in risk of hepatocellular carcinoma. 4, 5 In developed countries, antibody to HCV (anti-HCV) has been found in approximately 0.5-2.0% of the general population and in less than 1% of blood donors. 4, 6 Hepatitis C virus is primarily transmitted by the blood-borne (parenteral) route, principally via intravenous drug use, and, to a much lesser extent, from contaminated blood transfusions or blood products. 4, 6 Multiple heterosexual partners and homosexual activity have also been implicated in transmission, although less frequently. [7] [8] [9] The epidemiology of HCV transmission in the developing world is less well understood. In Peru, 10 a very low HCV seroprevalence (Ͻ 1%) was found in 1992 among high risk groups in Lima such as prostitutes, homosexuals, and sexual contacts of individuals seropositive for human immunodeficiency virus-1 (HIV-1). Moreover, no evidence of infection was found among indigenous villagers, soldiers, and oil field workers in the northern, selvatic region of Iquitos. No subsequent, population-based, HCV seroprevalence studies among Peruvians have been published. Thus, the relative frequency and importance of risk behaviors such as past medical and dental procedures, health care employment, and * Deceased. transmission via contaminated blood and blood products is unknown.
In this study, we sought to investigate the prevalence of HCV infection among Peruvians living in the metropolitan area of Lima, to include an estimation of the anti-HCV seroprevalence in volunteer blood donors and high-risk groups. We also endeavored to identify the HCV genotypes associated with infection among these groups.
PATIENTS, MATERIALS, AND METHODS

Study populations.
Data and blood samples were collected from patients presenting to five major blood donor centers, two hemodialysis units, one hemophilia center, and four gastroenterology inpatient units in Lima, Peru. To be considered for testing, serum samples had to be obtained from pre-determined risk groups to include blood donors, patients undergoing hemodialysis, hemophiliacs, and patients admitted for acute or chronic hepatitis. Two groups of sera were used in this study. The first group (cohort A) included samples provided during the period of 1986-1993 for a previous HIV seroprevalence study. A comparison group of patients at the same medical centers previously surveyed in 1986-1993 was sampled during March 1994 and constituted cohort B. Samples were collected sequentially from each location. For the second cohort, a sample of individuals undergoing drug abuse rehabilitation at two centers in Lima was also included.
For patients admitted to the hospital with a diagnosis of hepatitis, the diagnosis did not specify non-A, non-B cases, but, included all types. Hepatitis patients, however, had to have a documented serum alanine aminotransferase (ALT) level of at least twice the upper limit of normal for the testing laboratory. Other non-viral causes for the increased ALT level were eliminated (such as hepatotoxic medications, congestive heart failure, shock, or acute alcoholic hepatitis). Each individual enrolled in this study completed an anonymous questionnaire that included demographic information (age, gender, level of education); risk group assignment (as above); a medical history that included previous hospitalizations, major surgeries, blood transfusions, transplants, medical injections, and dental visits within the previous year; a history of a hepatitis-like illness or prior contact with a patient with hepatitis; use of intravenous (IV) drugs; a history of tattoos; and prior sexual exposure history and orientation. The study protocol was approved by the Institutional Review Board (IRB) of the Peruvian Navy Surgeon General, as well as by the IRB of the U.S. Navy Medical Research Institute. The U.S. Navy guidelines for the use of human subjects were followed.
Anti-HCV serologic testing. Serum was separated from each sample and transferred to cryogenic vials for further storage and testing. All samples were kept at Ϫ70ЊC prior to testing and identified only by a study number. All serologic testing was done in a blinded fashion by U.S. Navy Medical Research Center Detachment collaborators in a precoded, anonymous fashion, without inclusion of the patient's name, personal identification number, or address.
All samples were tested initially by a second generation enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (HCV EIA version 2.0; Abbott Laboratories, Abbott Park, IL). Samples that showed a reading above the test's cut-off value were retested a second time by ELISA. Repeatedly reactive sera were then tested using a second generation recombinant immunoblot assay (RIBA) according to the manufacturer's instructions (RIBA version 2.0; Chiron Corporation, Emeryville, CA). The RIBA test results were interpreted as follows: positive if 2 or more bands were detected at an intensity Ն 1ϩ, indeterminate if only one band was detected (regardless of intensity), and negative if no bands were detected. Samples that were repeatedly reactive by ELISA but negative or indeterminate by RIBA were considered negative.
HCV genotyping. Fifty archived serum samples, repeatedly reactive for anti-HCV by ELISA and RIBA positive, were screened by a direct reverse transcriptase-polymerase chain reaction (RT-PCR) method. Serum samples were reverse transcribed and amplified without prior purification. 11 Three microliters of each sample was added to an RT-PCR master mixture containing two separate sets of primer pairs specific for the 5Ј-UTR region.
12,13 A nested PCR method was used that consisted of two successive amplification processes that were carried out in the same tube.
The PCR products were examined after electrophoresis in a 1.4% agarose gel and staining with ethidium bromide. Positive samples were digested with two sets of restriction enzymes for genotyping: Mva I/Hinf I and Rsa I/Hae III. Subsequently, subtyping of genotype 1 was done using the restriction endonuclease Bst U-1, while subtyping of genotype 2 was performed using ScrF I. Table 1 summarizes the use of restriction enzymes for HCV genotyping. 14 Statistical analysis. Data were entered and analyzed in a computer database (SPSS version 7.5; SPSS, Inc., Chicago, IL). Differences in HCV seroprevalence for the demographic (age, sex, and education) variables and risk groups in the study were tested for significance by chi-square and Fisher's exact tests (two-tailed). Risk factors found to be important in univariate analysis or believed to be potential confounders were included in an unconditional multivariate logistic regression model (adjusting for age and gender). Presence of anti-HCV was used as the main outcome and risk was expressed as adjusted odds ratios (AORs) with associated 95% confidence intervals (95% CIs).
RESULTS
A total of 2,827 serum samples were tested: 1,389 from cohort A and 1,438 from cohort B. Table 2 shows a comparison of the two study cohorts. Relatively more young children (0-9 years old) participated in the first cohort (14%) compared with the second cohort (1%). Blood donors constituted approximately 60% of both groups; drug users were surveyed only in 1994.
Anti-HCV seroprevalence rates were 15.6% (216 of 1,389) for those in cohort A and 11.7% (168 of 1,438) in cohort B. The breakdown of anti-HCV seroprevalence rates by age, gender, educational level, and risk group is shown in Table 3 . Higher prevalence was noted in older individuals (Ն 40 years old), among females, and in less-educated persons. A higher seroprevalence rate was also noted in hemodialysis and hemophiliac patients compared with blood donors. Rates were also found to be increased from 1986 to 1993 to the 1994 period in hemodialysis patients and in hemophiliacs.
Analysis of medical and clinical risk factors for HCV infection is shown in Table 4 . For individuals surveyed in 1986Ϫ1993, those with a history of hepatitis, hospitalization, prior transfusions, organ transplantation, or medical injections were at significantly higher risk. Among subjects surveyed in the most recent (1994) cohort, the risk was also found to be increased for those with a history of major surgery, acupuncture, and a dental procedure within the preceding 12 months. Lastly, for those in the most recent cohort, the presence of symptoms of excessive tiredness and anorexia was found to be predictive of HCV infection and the presence of coluria was found to exclude an HCV diagnosis.
Analysis of behavioral and sexual risk factors for HCV infection is shown in Table 5 . Intravenous drug use was as- * NA ϭ data/serum not available. † P Ͻ 0.001 for increasing trend with age, for higher rate in females, and for higher rate in hemodialysis and hemophiliac patients compared with blood donors. ‡ P ϭ 0.001 for increasing trend in HCV rate with lesser education. § P Ͻ 0.001 for higher HCV seroprevalence in cohort B compared with cohort A. ¶ P ϭ 0.03 for higher HCV seroprevalence in cohort B compared with cohort A.
sociated with an increased risk of HCV infection; risk was estimated to be more than three-fold higher than for those who did not use intravenous drugs. The HCV infection risk was found to be significantly lower for volunteer blood donors in both study cohorts. A significant decrease in HCV infection risk was also noted for those sexually active within the previous year, as well as for males who had reported sexual contact with prostitutes. The use of condoms was not clearly correlated with the risk of HCV infection; risk was found to be higher for condom users (Ն 50% of the time) in the first study cohort (AOR ϭ 3.06), and paradoxically, lower risk was documented for condom users in the second study cohort (AOR ϭ 0.21). No increase in risk was noted for subjects with a history of tattoos or for those with a * HCV ϭ hepatitis C virus; AOR ϭ adjusted odds ratio (age-and gender-adjusted); CI ϭ confidence interval; IV ϭ intravenous; NA ϭ data not available; AIDS ϭ acquired immunodeficiency syndrome.
† P Ͻ 0.05. ‡ P Ͻ 0.01.
homosexual or bisexual orientation. We also found a significantly increased risk of past HCV infection among patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) in the first cohort but not in the second cohort (AOR ϭ 2.57).
A total of 50 samples were chosen at random for genotyping from the 384 anti-HCV positive specimens in our study. This constituted approximately 13% of all HCV-positive sera in out study. Three different genotypes were identified in this study ( Table 6 ). The most prevalent HCV genotype was type 1 (86%), followed by type 3 (10%) and type 2 (2%). One sample was untypable by the methods used here. By using Bst U-1, the genotype 1 samples were subtyped: 37 of these were identified as subtype 1a and six were identified as subtype 1b. The single genotype 2 sample was identified as subtype 2a by using ScrF I. The five genotype 3 samples were not subtyped.
DISCUSSION
Chronic infection with HCV constitutes a serious threat to the world's public health in the next century; as many as 3.9 million people in the United States 2,3 and 200 million people worldwide are estimated to have been infected. 18 It is largely unknown to what extent HCV affects many of the world's developing countries. Our study represents the first largescale effort to examine the prevalence of infection and genotype distribution among Peruvians across many different risk groups. However, its results have to be taken with caution, especially since the estimates of anti-HCV seroprevalence rates for the first study cohort (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) ) are based on a relatively long eight-year period (period prevalence) compared with one point in time (i.e., March 1994) for the second study cohort (point prevalence).
Our finding that HCV seroprevalence was significantly higher in older individuals (Ͼ 39 years of age), as well as in less-educated persons, parallels data found in the general population of the United States, in which seroprevalence has been found to be higher in those 30-49 years of age 9 and in persons of low socioeconomic level. 19 However, the higher seroprevalence found in Peruvian females is at variance with what has been found in large-scale studies in other countries. 3, 20 It is possible that this finding is a reflection of, as yet unidentified, risk factors; further studies in this population are needed to better assess the reason(s) for such a female gender-associated risk. It is reassuring to see that the HCV infection rate among volunteer blood donors appears to be low and following a decreasing trend, much as what has been seen to occur in industrialized countries since the advent of screening policies for exclusion of donors with HIV infections, donors with surrogate markers for non-A, non-B hepatitis, and the implementation of universal donor screening for anti-HCV in 1990. 21, 22 Similar policies have also been in effect in Peruvian blood banks for the past decade. Indeed, after adjusting for age and gender effects (Table 5) , we found that the risk among volunteer blood donors was only 2-8% that of non-donors. This constitutes further evidence of the efficacy of blood donor screening practices in Peru. The risk of prior HCV infection among transfusion recipients was found to be very high (approximately 27.5-29.8-fold higher in both study cohorts). The HCV infection risk was also found to be approximately 29.1-fold higher for prior organ transplant recipients, but only for the second cohort study (1994) . This documented higher risk of HCV infection found among subjects who had received prior blood transfusions and/or organ transplants (Table 4 ) may reflect acquisition of infection prior to implementation of anti-HCV screening in the early 1990s.
The high levels of HCV infection found among patients undergoing chronic hemodialysis and hemophiliacs are not surprising. The Centers for Disease Control and Prevention has estimated that the prevalence rates among persons with hemophilia treated with products made before 1987 is approximately 87%, with rates among hemodialysis patients as high as 64%. 23 It is possible that HCV transmission may have occurred in hemodialysis units in Lima because of faulty implementation of infection control practices, such as the sharing of medication vials and supplies. 24 In our study, we were not able to discern the specific reasons for this high rate. What is important to note, however, is the increasing trend noted in these two high-risk groups (as well as in the population of patients with chronic hepatitis).
We documented a consistently higher risk for HCV infection among individuals who reported a history of intravenous drug use, with a risk more than three-fold higher that for non-users (Table 5 ). Due to the prohibitive costs of hardcore type drugs (such as heroine and cocaine) in Peru, use of intravenous drugs is not as common among drug users as it is in the United States. However, the slight increase in risk noted between the periods of 1986 to 1993 (AOR ϭ 2.73) and 1994 (AOR ϭ 3.51) should raise concerns and may be a preamble of increased transmission. With a more steady economy, lower unemployment, and better means and access to these drugs now than 10-15 years ago, it is likely that parenteral drug use will continue to be an important route of transmission for HCV infection among young Peruvians.
An important finding in this study constitutes the suggested increased risk of HCV infection among individuals receiving parenteral medications or vaccines, for those visiting a dentist within the preceding year (only for the second study cohort), and for those reporting a history of prior acupuncture (data available only for the second study cohort). However, the risk was found to be relatively less important (as judged by AORs close to unity) than other recognized medical risk practices such as major surgeries, transfusions, or transplants. It is possible that parenteral exposures represent important routes of HCV transmission in Peru. As an illustration of that possibility, data obtained from female sex workers in Lima 25 also has shown an association between prior infection with hepatitis B virus and a history of receiving prophylactic penicillin injections to prevent syphilis. Case-control and cross sectional studies in Europe and Egypt have also suggested a significantly increased risk of spread of HCV via unsafe medical injection practices. 26 In addition, iatrogenic transmission during anti-schistosomal therapy programs in Egypt in the 1980s have been recently linked to very high levels of HCV infection. 27 Our findings, in conjunction with similar findings from other moderate or highly endemic countries where risk has been associated with medical practices, [26] [27] [28] seem to be sufficient to warrant further investigation of this potential for iatrogenic transmission of HCV in Peru.
Sexual transmission continues to be a very controversial area in HCV epidemiology. 8 Sexual (and non-sexual household) exposures have been poorly ascertained in previous studies. 29 However, available data from heterosexual and homosexual persons exhibiting high-risk sexual practices, has shown that the risk is increased with a greater number of sex partners, a history of sexually transmitted diseases (STDs), and failure to use condoms. 4, 8, 9, [30] [31] [32] In a recently published review, it has been stated that there is a small but definite risk of sexual transmission of HCV. 33 However, the risk for sexual transmission in Lima appears to be low. This mode of infection is less efficient than percutaneous exposures and it is very likely that such transmission has decreased in Peru (as it has in the United States) because of changes in risk behaviors due to the AIDS epidemic. 10, 19 Future, more intensive follow-up studies of STD patients, prostitute, and highly-active homosexual and heterosexual populations in Peru are urgently needed.
Genotyping of HCV is now considered an important issue because the viral type is thought to play a role in the mode of transmission, prognosis, therapy, and may be important for vaccine development. However, the role that HCV genotypes play in the disease severity and subsequent risk for development of hepatocellular carcinoma remains controversial. Confounding factors that prevent clear association of genotypes with disease outcome include lack of data from large, long-term, longitudinally studied homogeneous cohorts of HCV-infected populations. 34 Although the relationship of HCV genotype with disease severity and progression remains unclear, there is more consensus among investigators as to the importance of viral genotype as a predictor of response to antiviral therapy. Studies support the idea that genotypes other than type 1 are more responsive to combination therapies of interferon and ribavirin. 34 We confirm the finding of Bukh and others 35 of HCV genotype 1 in Peru, and we now report two additional genotypes, types 2 and 3. This preliminary study of genotyping HCV in Peru using RT-PCR followed by restriction fragment length polymorphism showed that at least three genotypes exist, including subtypes 1a, 1b, and 2a being identified. The genotypic pattern of HCV observed in these limited number of samples, the majority of infections being genotype 1 with some genotype 2 and 3 infections, is similar to the pattern seen in the United States and Europe.
There is a growing body of research data that indicates that the epidemiology of HCV in developing countries is significantly influenced by iatrogenic transmission factors. 26, 28 Further research is needed to understand the role of medical care practices in HCV transmission and to develop preventive measures in the context of health care systems in developing countries.
